High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial

Abstract

Moxifloxacin-based triple therapies showed higher eradication rates with few side effects and good drug compliance when compared with standard H. pylori treatments. Moreover, the increased prevalence of clarithromycin resistance suggests that moxifloxacin-based regimens could be safe and effective options in treatment of H. pylori infection.

Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials

“…And the data on the primary resistance to moxifloxicin are limited. Only Bago et al reported a low resistance rate of 5.9% in Croatia, as far as we know (21).…”

“…Of seven potential eligible articles, we excluded two more articles as the moxifloxacin-based therapy was used as second-line treatment for Helicobacter pylori infection (23,26) and one paper without standard triple therapy as contrast group (24). Finally, four RCTs (n=772 patients) were included which compared moxifloxacin-based triple therapy to clarithromycin-based triple therapy (21,27,29,35). The quality of the included studies is shown in Table 1.…”

“…The included patients did not differ in baseline characteristics (disease and sex) (see Table 2). The results of the four studies are summarized in Table 3 (21,27,29,35 Fig. 2).…”

“…2). Three trials compared the incidence of side effects of moxifloxacin-based triple therapy versus clarithromycin-based triple therapy (21,27,35). The incidence of adverse events is summarized in Fig.…”

“…In recent years new treatment schemes based on fluoroquinolones have been under investigation (21)(22)(23)(24)(25)(26)(27)(28)(29); however, first-generation fluoroquinolones such as norfloxacin and pefloxacin did not show satisfactory eradication rates (30,31). Several studies have evaluated the efficacy of different levofloxacin-based triple therapies and shown eradication rates up to 90% (22,27).…”